TD Cowen raised the firm’s price target on Danaher (DHR) to $260 from $250 and keeps a Buy rating on the shares. The firm updated its model following Q3 results and said accelerated cost cuts into what could be an easier recovery in 2026 offered a clearing event for believers in the company’s bioprocess-driven story despite a mixed print/guide.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target raised to $247 from $236 at Baird
- Danaher Corporation Reports Strong Q3 2025 Results
- Danaher: Strong Growth Potential Amid Conservative Outlook and Strategic Reinvestment
- Midday Fly By: GM, Coca-Cola report Q3 beats
- Early notable gainers among liquid option names on October 21st